Phase II study of weekly high dose fluorouracil in previously treated patients, with metastatic colorectal cancer

Journal of Chemotherapy

Volumn 12, Issue 2, 2000, Pages 183-185

  Mermershtain, Wilmosh ^a   Lavrenkov, K ^a   Cohen, Y ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Colorectal cancer; Fluorouracil; High dose fluorouracil; Metastatic colorectal cancer; Phase II study

Indexed keywords

FLUOROURACIL;

AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; MALE; METASTASIS; NAUSEA; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; VOMITING;

EID: 0034061997     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2000.12.2.183     Document Type: Article

References (6)

1. 1 MacMillan WE, Wobery WH, Welling PG. Pharmacokinetics of 5-fluorouracil in humans. Cancer Res 1978; 38: 3479-82.
2. 2 Shackney SE. Cell kinetics and cancer chemotherapy: In Calabresi P, Schein PS, Rosenberg SA (eds): Medical Oncology, New York, MacMillan, 1985: 41-60.
3. 3 Lokich JJ, Bothe A, Fine N, Perri J. Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 1981; 48: 2565-8.
4. 4 Sotos GA, Grogan L, Allegra CJ. Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treat Rev 1994; 20: 11-49.
5. 5 Piedbois P, Buyse M, Rustum Y et al. Modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer: a meta-analysis. Proc Annu Meet Am Soc Clin Oncol 1992; 11: A483.
6. 6 Benson AB. Regional and systemic therapies for advanced colorectal carcinoma: randomized clinical trial results. Oncology-Huntingt. 1998; 12 (10 Suppl 7): 28-34.